Ribociclib/ET Combo Extends Survival in Premenopausal Breast Cancer

For patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, combination therapy with a cyclin-dependent kinase (CDK) 4/6 inhibitor and endocrine therapy (ET) is standard first-line therapy for both postmenopausal and premenopausal patients based on substantial improvement of progression-free survival (PFS) in randomized phase III trials. However, significant improvement […]

Read More

Maintenance Olaparib Prolongs PFS in BRCA-Mutated Pancreatic Cancer

The prognosis of patients with metastatic pancreatic cancer (mPCA) remains poor, despite use of modern chemotherapy regimens such as FOLFIRINOX and nab-paclitaxel/gemcitabine. After progression on frontline therapy, less than half of the patients are eligible for second-line treatment. There is a high, unmet need for targeted biomarker selected treatment approaches. In ovarian and breast cancer, […]

Read More

Enzalutamide Improves Survival in Hormone-Sensitive Prostate Cancer

The treatment of metastatic hormone-sensitive prostate cancer (HSPC) has undergone a major evolution in recent years. While androgen deprivation therapy (ADT) remains the backbone of care, several studies have demonstrated an improvement in long-term survival when the cytotoxic agent docetaxel or the androgen biosynthesis inhibitor abiraterone are added to ADT. Enzalutamide is a potent direct […]

Read More

Pembrolizumab ± Chemotherapy, a New First-Line Standard for HNSCC

For the past decade, the standard first-line treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) has been the combination of cetuximab, platinum chemotherapy, and 5-FU followed by cetuximab maintenance, commonly referred to as the “EXTREME regimen.” However, while this regimen results in a 10.1-month overall survival (OS), it is associated […]

Read More

New Oncology and Hematology Indications Approved by FDA in May

PI3K Inhibitor Alpelisib for PIK3CA-mutated Advanced Breast Cancer. The phosphoinositide 3-kinase (PI3K) inhibitor alpelisib (Piqray®, Novartis Pharmaceuticals Corporation) was approved for use in combination with fulvestrant for treatment of postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer following progression on or after an endocrine containing regimen. To […]

Read More